More than 80 percent of U.S. HIV transmissions in 2016 were from people who were unaware of their status or had been diagnosed but lost to follow-up.
Experts push for normalization of PrEP; U.S. HIV transmission rates across the care continuum; sociodemographic disadvantage and HIV drug resistance; real-world success of integrase inhibitors for treatment-experienced people.
Impact of intimate partner violence on PrEP attitudes among women; evolution of first-line HIV treatment failure rates; cumulative low-level viremia and virologic failure risk; HIV drug levels in breast milk versus plasma.
A CROI 2019 study suggests the dynamics of HIV proliferation in the viral reservoir might explain why viral load sometimes fails to become undetectable, especially when adherence is good.
Atripla may be just as effective when taken every other day; poor antiretroviral prescription fill rates after hospitalization; U.S. progress against UNAIDS targets; hepatitis C transmission clustering in France.
Internalized HIV stigma, depression, and adherence in women; what “internalized HIV stigma” actually means; tenofovir-containing gel and genital herpes prevention; the neurocognitive effects of cerebrospinal HIV escape.
A Canadian study of this cost-saving approach found high acceptance of de-simplification among people already on a single-tablet regimen, and even higher rates among people who were just initiating single-tablet treatment.
Alternate PrEP guideline recommendations; partner notification and onward HIV transmission; shifting causes of death among HIV/HCV-coinfected people; correlates of lower adherence among people on methadone maintenance.
Integrase inhibitors are associated with greater increases in body weight than other antiretrovirals, especially among women and black people. But it's unclear whether these changes are clinically significant.
Cholesterol guidelines may underestimate statin value; shifting from Ryan White CARE Act to Affordable Care Act coverage; HCV seroconversion and CD4 count suppression; HCV reinfection odds by risk group.